Segal J - Search Results

1

Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysis.

Rothmann M, Crown W, Louis TA, Permutt T, Ruberg S, Segal J, Scott J. Rothmann M, et al. Among authors: segal j. Pharm Stat. 2021 Sep;20(5):952-964. doi: 10.1002/pst.2077. Epub 2020 Oct 28. Pharm Stat. 2021. PMID: 33118319

2

Diagnosis of crystal-induced arthritis by synovial fluid examination for crystals: lessons from an imperfect test.

Segal JB, Albert D. Segal JB, et al. Arthritis Care Res. 1999 Dec;12(6):376-80. doi: 10.1002/1529-0131(199912)12:6<376::aid-art5>3.0.co;2-5. Arthritis Care Res. 1999. PMID: 11081008 Review.

3

A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research.

Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. Varadhan R, et al. J Clin Epidemiol. 2013 Aug;66(8):818-25. doi: 10.1016/j.jclinepi.2013.02.009. Epub 2013 May 4. J Clin Epidemiol. 2013. PMID: 23651763 Free PMC article. Review.

4

Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.

Baksh SN, McAdams-DeMarco M, Segal JB, Alexander GC. Baksh SN, et al. Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):660-667. doi: 10.1002/pds.4437. Epub 2018 Apr 14. Pharmacoepidemiol Drug Saf. 2018. PMID: 29655237 Free PMC article.

5

The evidence regarding the drugs used for ventricular rate control.

Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson K, Yu D, Bass EB. Segal JB, et al. J Fam Pract. 2000 Jan;49(1):47-59. J Fam Pract. 2000. PMID: 10678340 Review.

6

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.

Mehta HB, Ehrhardt S, Moore TJ, Segal JB, Alexander GC. Mehta HB, et al. Among authors: segal jb. BMJ Open. 2020 Jun 9;10(6):e039978. doi: 10.1136/bmjopen-2020-039978. BMJ Open. 2020. PMID: 32518212 Free PMC article.

7

Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations.

Segal JB; PRIORITIZE HCV Study Group. Segal JB, et al. Clin Trials. 2020 Dec;17(6):729-731. doi: 10.1177/1740774520941257. Epub 2020 Jul 10. Clin Trials. 2020. PMID: 32650667 No abstract available.

8

Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research.

Snyder CF, Jensen RE, Segal JB, Wu AW. Snyder CF, et al. Med Care. 2013 Aug;51(8 Suppl 3):S73-9. doi: 10.1097/MLR.0b013e31829b1d84. Med Care. 2013. PMID: 23774513 Free PMC article.

9

Forces influencing generic drug development in the United States: a narrative review.

Lee CY, Chen X, Romanelli RJ, Segal JB. Lee CY, et al. Among authors: segal jb. J Pharm Policy Pract. 2016 Sep 22;9:26. doi: 10.1186/s40545-016-0079-1. eCollection 2016. J Pharm Policy Pract. 2016. PMID: 27688886 Free PMC article. Review.

10

If we recognize heterogeneity of treatment effect can we lessen waste?

Segal JB, Varadhan R. Segal JB, et al. J Comp Eff Res. 2019 Oct;8(14):1143-1145. doi: 10.2217/cer-2019-0118. Epub 2019 Oct 1. J Comp Eff Res. 2019. PMID: 31571494 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,079 results

Search Page

Filters